HDL Therapeutics, a privately held commercial stage biotech company, agreed to go public via a SPAC merger with Swiftmerge Acquisition, a special purpose acquisition company, in a $480m deal. “We are thrilled to partner with Swiftmerge and hope to bring our groundbreaking treatment to appropriate patients around the world. Our treatment has the potential to benefit countless lives with the hope of one day eradicating coronary atherosclerosis as we know it,” Michael Matin, HDL Therapeutics Chairman and CEO.